Global Security Newswire
Daily News on Nuclear, Biological & Chemical Weapons, Terrorism and Related Issues
NIAID Awards $9.4M for Anthrax Vaccine Project
A New Jersey firm has won $9.4 million in federal funding for work on a new anthrax vaccine in conjunction with Harvard University, the Times of Trenton reported on Tuesday (see GSN, Oct. 12, 2011).
The funds, provided by the U.S. National Institute of Allergy and Infectious Diseases, would support efforts by the biopharmaceutical company Soligenix to create an anthrax countermeasure that would be capable of conferring immunity with only one dose and remain effective following long periods in storage.
"If long-term stability were achieved, the vaccine would have the potential to be stockpiled for general use and for postexposure prophylaxis,” Soligenix head Christopher Schaber said.
Washington has awarded more than $4 billion to date for efforts to develop superior anthrax vaccines that could be administered before or after exposure to the bacteria, according to the report (David Karas, Times of Trenton, Jan. 3).
Note to our Readers
GSN ceased publication on July 31, 2014. Its articles and daily issues will remain archived and available on NTI’s website.
Oct. 6, 2014
The UNSCR 1540 Resource Collection examines implementation of United Nations Security Council Resolution 1540, which requires all states to implement measures aimed at preventing non-state actors from acquiring NBC weapons, related materials, and their means of delivery. It details implementation efforts in all of the regions and countries of the world to-date.
This article provides an overview of the United States’ historical and current policies relating to nuclear, chemical, biological and missile proliferation.